Should the government ban disease awareness campaigns?

                        - Ganadhish Kamat

India’s recent caution by the Central Drugs Standard Control Organization (CDSCO) against indirect promotion of weight-loss drugs—particularly GLP-1 analogues—has reopened an important policy debate: where should regulators draw the line between unethical drug promotion and legitimate public health communication?

At first glance, the concern is understandable. India’s Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954 was designed to protect citizens from misleading claims and exploitative marketing, especially for conditions like obesity, diabetes, cancer, and neurological disorders. The spirit of the law is clear—prevent commercialization of hope.

However, conflating disease awareness campaigns with drug advertising risks undermining an equally important public health objective: informed citizens.

Awareness is not Advertising

A disease awareness campaign, by definition, educates the public about symptoms, risk factors, prevention, and the importance of seeking medical care. It does not promote a specific drug or brand. The distinction is subtle but critical.

India has long benefited from such campaigns:

• Nationwide HIV awareness efforts during the early 2000s, led by the National AIDS Control Organisation, helped reduce stigma and improve testing rates.

• Tuberculosis campaigns under the Revised National Tuberculosis Control Programme encouraged early diagnosis and adherence to treatment.

• Public messaging around cancer screening and mental health has steadily improved early detection and care-seeking behavior.

None of these campaigns promoted a specific drug. Yet, they undoubtedly increased demand for diagnosis and treatment—exactly what a functioning healthcare system should encourage.

The Case of Obesity and GLP-1 Therapies

Obesity is not merely a lifestyle issue; it is a chronic disease with metabolic, cardiovascular, and psychological consequences. Despite this, it remains underdiagnosed and undertreated in India due to stigma and lack of awareness.

The emergence of GLP-1 receptor agonists—such as Semaglutide and Liraglutide—has transformed the treatment landscape. These therapies offer clinically meaningful weight loss and reduction in cardiovascular risk for certain patient populations.

In such a context, disease awareness campaigns serve a legitimate purpose:

• They reframe obesity as a medical condition rather than a moral failing.

• They inform patients that evidence-based treatments exist.

• They encourage consultation with qualified healthcare professionals.

Suppressing such communication may inadvertently perpetuate ignorance and stigma—arguably a greater public health risk.

A Regulatory Paradox: Selective Stringency

While modern pharmaceuticals face increasing scrutiny—even at the level of disease awareness—there is a visible and persistent regulatory asymmetry in India.

Ayurvedic and “natural” products are routinely advertised across television, print, and digital media for conditions explicitly covered under the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954.

Examples are ubiquitous:

• Patanjali Divya Medohar Vati promoted for weight reduction

• Himalaya Liv.52 & Kapiva Liver care juice marketed for liver health, including fatty liver

• Dabur Rheumatil Oil & Kapiva Arthro sure juice advertised for joint and rheumatic pain

• Numerous polyherbal formulations claiming to “manage” or “reverse” diabetes

These campaigns often go beyond awareness:

• They directly or indirectly claim efficacy

• They use testimonials and before-after narratives

• They rarely emphasize medical consultation or diagnostic confirmation

Yet, enforcement appears uneven.

The Consequences of Dual Standards

This regulatory duality has broader implications:

1. Distorted Public Perception
When evidence-based therapies are muted while less rigorously validated products are widely advertised, patients may equate both as equally credible—or worse, trust the more visible option.

2. Delayed Evidence-Based Treatment
Patients with conditions like diabetes, fatty liver disease, or obesity may delay seeking scientifically proven treatments in favor of heavily marketed alternatives.

3. Unintended Stigma Against Modern Medicine
Restricting even awareness campaigns for modern therapies can create a perception that such treatments are either unsafe or controversial.

4. Regulatory Credibility at Risk
Inconsistent enforcement weakens the moral authority of regulation and invites questions about fairness and scientific alignment.

Learning from Global Regulatory Practices

Regulators like the U.S. Food and Drug Administration and the European Medicines Agency recognize the distinction between disease awareness and promotion. They allow “help-seeking” communications with clear guardrails:

• No mention of specific products

• Balanced, evidence-based messaging

• Encouragement to consult healthcare professionals

India can adopt a similar approach—while also ensuring that all systems of medicine are held to comparable standards of evidence and advertising ethics.

The Risk of Overcorrection

An overly restrictive interpretation of the law may have unintended consequences:

• Delayed diagnosis: Patients remain unaware of symptoms or seriousness of conditions.

• Health inequity: Only well-informed or urban populations seek advanced treatments.

• Stifled innovation uptake: Breakthrough therapies fail to reach eligible patients.

Ironically, such outcomes run counter to the very purpose of drug regulation—improving public health.

A Balanced Way Forward

Rather than restricting disease awareness campaigns, CDSCO could refine its framework:

1. Uniform Enforcement Across Systems
   Apply the same advertising standards—whether for allopathic, ayurvedic, or other products.

2. Clear Definition of Disease Awareness
   Allow campaigns that are non-branded, educational, and patient-centric.

3. Stronger Oversight of Claims
   Ensure that any therapeutic claims—across all systems—are backed by credible evidence.

4. Transparency in Sponsorship
   Disclose funding sources for all campaigns, including those by traditional medicine companies.

This approach preserves the integrity of the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954 while enabling responsible public health education.

Conclusion

In a country as complex as India, awareness is often the first step toward care. Disease awareness campaigns—when responsibly designed—are not marketing loopholes but public health tools.

However, credibility in regulation depends not just on intent, but on consistency. If evidence-based therapies are tightly restricted while unverified claims proliferate elsewhere, the system risks sending mixed signals to patients.

The goal should not be to silence awareness—but to ensure that all health communication, regardless of its origin, is truthful, responsible, and aligned with patient welfare.

Because ultimately, an informed patient should be guided by science—not by who advertises more loudly.